THE PEOPLE BEHIND THE WORK
Expertise at the Ready.
Built for the Work When It Matters Most.
Senior practitioners on day one. The same people in the room at month six. Each one has carried what you're carrying and stayed until the work held.
THE TEAM
The people who do the work.
Every engagement is led by a senior practitioner who has carried what you're carrying; the science, the timeline, the board, and the team simultaneously. We know what that weight feels like. We don't add to it.
The commercial infrastructure that determines whether a therapy reaches patients doesn't build itself. He builds it from the ground up for pre-commercial and emerging biopharma, where the first wrong decision determines the next eighteen months. The depth comes from having seen those same decisions play out at global scale.
W.H. Alvin Mok
Managing Partner
Transformation & Commercial Operations
Paul Bragoli
Managing Partner
Market Access
He has spent his career inside the payer conversation. Across PBMs, national and regional plans, and the formulary committees that decide whether a therapy gets covered, gets restricted, or gets buried. He knows what moves payers, what stalls them, and where the leverage actually sits. That distinction is the whole job.
Early-stage companies don’t fail on science alone. They fail when the path from approval to adoption isn’t built. She shapes that path; commercial strategy, investor narrative, and the operating model required to turn an asset into a business.
Meghan Rivera
Executive Advisor
Commercialization Strategy
Veron Browne, PhD
Translational & Clinical Strategy
Most organizations treat the transition from R&D to regulatory and commercial as a handoff. He treats it as the most consequential moment in the asset's life. Translational science, clinical strategy, and the evidence architecture that determines whether the molecule survives the gap between approval and access. The handoff is where assets get lost. He makes sure they don't.
Craig Salmon-Gilmore
Commercial Effectiveness & Field Operations
He knows the difference between a formulary win and formulary pull-through. One is on paper. The other is what the field does every day after the access decision is made. That gap is where commercial performance either holds or quietly falls apart. Closing it is the work.
Andy Joslyn
Trade & Channel Strategy
Thirty-one years of commercial pharma experience. Specialty pharmacy, trade, distribution, and the contracted relationships that determine whether a therapy actually reaches the patient. He has built the networks from scratch and run them at scale. The channel is where most launches quietly succeed or quietly fail.
Operators with scars
Our team has built and rebuilt commercial infrastructure where every gap shows up in the timeline. The cost is measured in patients.
​
Each senior practitioner on this team has carried it before. That's the only way we know how to do this work.
